Press Releases

The CEO of Aurora BioPharma is a Featured Guest on CBS in a Discussion on Cancer Research in Pediatrics

CAMBRIDGE, MA - April 1, 2016 - Aurora BioPharma, Inc. CEO, Robert Brooks, is joined by Raymond Rodriguez-Torres, Chairman of the “Live Like Bella” Childhood Cancer Foundation on the set of CBS Miami public affairs show “Focus On South Florida”, hosted by Rudabeh Shahbazi. The panelists discussed the newest research aimed at finding a cure for pediatric cancer. Organizers urged Congress to enact the “Bella Bill” – legislation focusing on cancer research in pediatrics – following resolutions passed by City of Miami and Miami-Dade County commissioners in support of the bill.

​The segment can be viewed here:

About "Live Like Bella" Childhood Cancer Foundation

The “Live Like Bella” Childhood Cancer Foundation was founded after the passing of Bella Rodriguez-Torres, who was diagnosed with Stage 4 Alveolar Rhabdomyosarcoma, an aggressive childhood cancer, at an early age. Bella passed away at the age of ten, leaving behind an indelible legacy. Thousands of mourners attended her funeral. In response to requests from Miami Heat fans, LeBron James and Dwayne Wade wrote “Live Like Bella” on their sneakers during play of the NBA Eastern Conference Finals. The Miami Marlins honored Bella with a "#LiveLikeBella" jersey hung in the dugout during an outing against the Tampa Bay Rays. The City of Miami Police Department named Bella “Honorary Chief.” And the county named a public park in Leisure City, “Live Like Bella Park” and a section of SW 107th Avenue “Live Like Bella Way.”

About Aurora BioPharma

Aurora is leading in the development of Chimeric Antigen Receptor (CAR) T therapy, Cancer Vaccines, and combinations with Checkpoint Inhibitors. AU105 is a "living-drug" CAR T agent that has shown safety and efficacy in pre-clinical and human clinical trials. A Phase 1 clinical trial was completed in 16 Glioblastoma patients, AU105 met its endpoints of safety, tumor killing efficacy, and showed promising signals of double the median historic overall survival. Aurora is planning a randomized multi-site Phase II trial of AU105 in Early Diagnosed Glioblastoma, and a Phase I/II trial in Recurrent Glioblastoma with intracranial injection. Osteosarcoma is the most common type of bone cancer in Children and Adolescents, even after radical amputation of a limb and chemotherapy, survival is poor. A Phase 1 trial in 19 Sarcoma patients was completed, AU-105 met its endpoints of safety, with strong signs of tumor killing efficacy. Aurora is planning a Phase II trial of its CAR T Cell therapy AU105 in Osteosarcoma. The Company also has an equity interest in MedVax Technologies, Inc., its p53 DC cancer vaccine MX-225 has completed a Phase II clinical trial in Small Cell Lung Cancer; and soon to complete a Phase II trial in Breast Cancer with Indoximod, an IDO inhibitor from NewLink Genetics. The Company is planning a combination trial with MX-225 and a PD-1 antibody in lung cancer with a major pharmaceutical company.

For media inquiries, please contact:

Candace Cobos

VP, Business Development & Public Relations

Harvard Square, One Mifflin Place, Suite 400

Cambridge, MA 02138

Tel: (617) 674-7718 - Fax: (617) 674-7701

Ingraham Building, 25 SE 2nd Avenue, Suite 504

Miami, FL 33131

Tel: (305) 371-2301 - Fax: (305) 371-2304 -

New Paradigm in Cancer Immunotherapy

Source: Aurora BioPharma, Inc.